Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Patrick Harrison Carroll sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total transaction of $331,050.00. Following the transaction, the insider now owns 196,941 shares in the company, valued at $4,346,487.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Hims & Hers Health Trading Up 0.9 %
Shares of NYSE:HIMS opened at $23.62 on Friday. Hims & Hers Health, Inc. has a 52 week low of $6.58 and a 52 week high of $25.74. The company’s 50 day moving average is $18.57 and its two-hundred day moving average is $18.33. The company has a market cap of $5.07 billion, a PE ratio of 53.68 and a beta of 1.06.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.
Institutional Trading of Hims & Hers Health
Wall Street Analyst Weigh In
HIMS has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday. Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Bank of America increased their price target on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. TD Cowen lifted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Finally, Piper Sandler reissued a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.
View Our Latest Analysis on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Recommended Stories
- Five stocks we like better than Hims & Hers Health
- How to Invest in Small Cap Stocks
- How Altimmune Could Grab a Big Chunk of the GLP-1 Market
- Top Biotech Stocks: Exploring Innovation Opportunities
- Here’s Why Etsy Management Is Investing $1 Billion in Buybacks
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks Poised to Ride America’s Manufacturing and Ag Revival
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.